
Please try another search
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer and is under phase 1 trial. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy and is under Phase Ib/IIa study; and SON-1210, a bispecific compound developed for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.
Name | Age | Since | Title |
---|---|---|---|
Donald J. Griffith | 73 | 2015 | Director |
Raghu Rao | 59 | 2019 | Independent Director |
Jason Bock | - | - | Member of Scientific Advisory Board |
Guido Cavaletti | - | - | Member of Scientific Advisory Board |
Hossein Borghaei | - | - | Member of Scientific Advisory Board |
Nailesh Bhatt | 49 | 2018 | Independent Director |
Albert D. Dyrness | 59 | 2019 | Independent Director |
Robert Wenham | - | 2022 | Member of Scientific Advisory Board |
Lori McNeill | - | 2022 | Director |
Pankaj Mohan | 58 | 2015 | Founder, Chairman, CEO & President |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review